Marqeta Analyst Turns Bullish, Sees ‘Clear Path To Profitability’
Marqeta Inc (NASDAQ: MQ) stock has experienced a selloff, hitting 52-week lows on Thursday.
Marqeta Analyst Turns Bullish, Sees ‘Clear Path To Profitability’
Marqeta Inc (NASDAQ: MQ) stock has experienced a selloff, hitting 52-week lows on Thursday.
Why Are Pinterest Shares Are Trading Higher On Monday?
Advertisers told analysts at UBS that Pinterest Inc (NYSE: PINS) is taking bolder steps under its new CEO Bill Ready to move more rapidly towards a significant improvement in ad efficacy that could ultimately drive budget and further monetization partnerships, something that UBS took as a cat
Why Are Pinterest Shares Are Trading Higher On Monday?
Advertisers told analysts at UBS that Pinterest Inc (NYSE: PINS) is taking bolder steps under its new CEO Bill Ready to move more rapidly towards a significant improvement in ad efficacy that could ultimately drive budget and further monetization partnerships, something that UBS took as a cat
Why Are Pinterest Shares Are Trading Higher On Monday?
Advertisers told analysts at UBS that Pinterest Inc (NYSE: PINS) is taking bolder steps under its new CEO Bill Ready to move more rapidly towards a significant improvement in ad efficacy that could ultimately drive budget and further monetization partnerships, something that UBS took as a cat
Benzinga’s Top Ratings Upgrades, Downgrades For March 24, 2023
Upgrades Argus Research upgraded the previous rating for Cracker Barrel Old Country Store Inc (NASDAQ:CBRL) from Hold to…
Benzinga’s Top Ratings Upgrades, Downgrades For March 24, 2023
Upgrades Argus Research upgraded the previous rating for Cracker Barrel Old Country Store Inc (NASDAQ:CBRL) from Hold to…
Benzinga’s Top Ratings Upgrades, Downgrades For March 24, 2023
Upgrades Argus Research upgraded the previous rating for Cracker Barrel Old Country Store Inc (NASDAQ:CBRL) from Hold to…
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met its prima
Pulte Homes Is Not ‘Boring’: Analyst Who Now Says Buy Explains Why
PulteGroup Inc. (NYSE: PHM), under the leadership of CEO Ryan Marshall, has ousted a second executive.